<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566134</url>
  </required_header>
  <id_info>
    <org_study_id>DA8010_OAB_II</org_study_id>
    <nct_id>NCT03566134</nct_id>
  </id_info>
  <brief_title>A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder</brief_title>
  <official_title>A Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Therapeutic Exploratory Clinical Study to evaluate the efficacy and safety of DA-8010 in
      Patients with Overactive Bladder and to determine the optimal dose of DA-8010
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in mean number of micturitions per 24 hours</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to Week 12 in mean number of micturitions per 24 hours</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DA-8010 placebo + Solifenacin succinate placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-8010 2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-8010 2.5mg + Solifenacin succinate placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-8010 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-8010 5mg + Solifenacin succinate placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DA-8010 placebo + Solifenacin succinate 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 Placebo</intervention_name>
    <description>Participants receive placebo to match DA-8010 orally once a day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Solifenacin 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 2.5mg</intervention_name>
    <description>Participants receive DA-8010 2.5mg orally once a day.</description>
    <arm_group_label>DA-8010 2.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 5mg</intervention_name>
    <description>Participants receive DA-8010 5mg orally once a day.</description>
    <arm_group_label>DA-8010 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin 5mg</intervention_name>
    <description>Participants receive solifenacin 5 mg orally once a day.</description>
    <arm_group_label>Solifenacin 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate placebo</intervention_name>
    <description>Participants receive placebo to match solifenacin 5 mg orally once a day.</description>
    <arm_group_label>DA-8010 2.5mg</arm_group_label>
    <arm_group_label>DA-8010 5mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main Inclusion at Screening (Visit 1):

          -  Men and women 19 years or older with OAB symptoms for â‰¥ 3 months.

          -  Subject who is willing and able to complete the micturition diary correctly.

          -  Subject who is willing and able to provide informed consent indicating that they
             understand the purpose and procedures required for the study

        Exclusion Criteria:

          -  Clinically significant Stress urinary incontinence or Mixed urinary incontinence where
             stress is the predominant factor

          -  Diagnosed with interstitial cystitis or bladder pain syndrome

          -  Clinically significant pelvic organ prolapse

          -  Subject who has neurologic status which is able to effect vesical function, such as
             multiple sclerosis, Spinal Injury or Parkinson's disease

          -  Medical history of malignant tumor in urinary system or pelvic organs

          -  Clinically significant bladder outlet obstruction or more than 200mL of post-void
             residual volume
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

